BlackRock’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-4,444,070
| Closed | -$213M | – | 5241 |
|
|
2020
Q1 | $213M | Sell |
4,444,070
-44,254
| -1% | -$2.06M | 0.01% | 1114 |
|
|
2019
Q4 | $211M | Sell |
4,488,324
-201,668
| -4% | -$8.91M | 0.01% | 1448 |
|
|
2019
Q3 | $111M | Buy |
4,689,992
+630,823
| +16% | +$18.7M | ﹤0.01% | 1833 |
|
|
2019
Q2 | $122M | Buy |
4,059,169
+886,583
| +28% | +$20.3M | 0.01% | 1772 |
|
|
2019
Q1 | $71.1M | Buy |
3,172,586
+527,325
| +20% | +$11.3M | ﹤0.01% | 2084 |
|
|
2018
Q4 | $48.1M | Buy |
2,645,261
+595,328
| +29% | +$9.35M | ﹤0.01% | 2265 |
|
|
2018
Q3 | $37.1M | Buy |
2,049,933
+512,602
| +33% | +$6.08M | ﹤0.01% | 2545 |
|
|
2018
Q2 | $15.3M | Buy |
1,537,331
+385,587
| +33% | +$2.66M | ﹤0.01% | 3014 |
|
|
2018
Q1 | $6.12M | Buy |
1,151,744
+199,164
| +21% | +$1.42M | ﹤0.01% | 3354 |
|
|
2017
Q4 | $8.1M | Buy |
952,580
+308,452
| +48% | +$3.79M | ﹤0.01% | 3253 |
|
|
2017
Q3 | $9.4M | Buy |
644,128
+22,799
| +4% | +$345K | ﹤0.01% | 3199 |
|
|
2017
Q2 | $11.6M | Buy |
621,329
+276,288
| +80% | +$6.23M | ﹤0.01% | 3081 |
|
|
2017
Q1 | $7.35M | Buy |
345,041
+327,934
| +1,917% | +$6.27M | ﹤0.01% | 3246 |
|
|
2016
Q4 | $260K | Buy |
+17,107
| New | +$233K | ﹤0.01% | 1975 |
|
Other funds holding RARX
BlackRock's RARX Position: Q2 2020 in Review
BlackRock sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 4,444,070 shares — an estimated $213M sold.
BlackRock first reported a position in RARX in Q4 2016 and held it in 14 quarters. The position peaked at $213M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.
- BlackRock reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
- BlackRock sold 4,444,070 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $213M.
- BlackRock first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 14 quarters.
- BlackRock's Ra Pharmaceuticals, Inc. Common Stock position peaked at $213M in Q1 2020.
- 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.
Based on BlackRock's 13F filing for Q2 2020, filed 14 Aug 2020.